CBDX (Curative Biosciences) LT-Debt-to-Total-Asset: 0.00 (As of Mar. 2018)


What is Curative Biosciences LT-Debt-to-Total-Asset?

Curative Biosciences CBDX LT-Debt-to-Total-Asset is 0.00 as of Mar. 2018.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Curative Biosciences's long-term debt to total assests ratio for the quarter that ended in Mar. 2018 was 0.00.

Curative Biosciences's long-term debt to total assets ratio stayed the same from Mar. 2017 (0.00) to Mar. 2018 (0.00).

Curative Biosciences  (OTCPK:CBDX) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Curative Biosciences LT-Debt-to-Total-Asset Related Terms

Curative Biosciences LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Curative Biosciences's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Curative Biosciences LT-Debt-to-Total-Asset Chart

Curative Biosciences Annual Data
Trend Jun08 Jun09 Jun10 Jun11 Jun12 Jun13 Jun14 Jun15 Jun16 Jun17
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Curative Biosciences Quarterly Data
Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Curative Biosciences LT-Debt-to-Total-Asset Calculation

Curative Biosciences's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jun. 2017 is calculated as

LT Debt to Total Assets (A: Jun. 2017 )=Long-Term Debt & Capital Lease Obligation (A: Jun. 2017 )/Total Assets (A: Jun. 2017 )
=0/0.002
=

Curative Biosciences's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2018 is calculated as

LT Debt to Total Assets (Q: Mar. 2018 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2018 )/Total Assets (Q: Mar. 2018 )
=0/0.014
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
Curative Biosciences (CBDX) has a LT-Debt-to-Total-Asset of 0.00 as of Mar. 2018. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Curative Biosciences and its competitors.
Is Curative Biosciences' LT-Debt-to-Total-Asset too high?
Curative Biosciences' current LT-Debt-to-Total-Asset is 0.00.
How does Curative Biosciences' LT-Debt-to-Total-Asset compare to ACUR and CVLB?
Curative Biosciences' LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?
A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Curative Biosciences and its competitors. Curative Biosciences's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curative Biosciences stock overvalued right now?
Curative Biosciences (CBDX) has a current LT-Debt-to-Total-Asset of 0.00. The current LT-Debt-to-Total-Asset is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Curative Biosciences (CBDX), the current LT-Debt-to-Total-Asset is 0.00 as of Mar. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Curative Biosciences Business Description

Address 2 South Biscayne Boulevard, Suite 3760, Miami, FL, USA, 33131
Curative Biosciences Inc is a life sciences company focused on developing and commercializing novel therapeutics using hemp-derived CBD. Its products comprise of CBD softgels, Hemp oil, and Topicals.